Everolimus
Everolimus (Afinitor) acts as an mTor inhibitor, targeting specific pathways involved in cell growth and metabolism. It is primarily used to address complex oncological conditions. Available formulations are listed below, with detail on the drug’s role in therapy.
Key points
- Blocks mTor, a protein that normally drives cell growth and division, cutting off the blood supply solid tumours need to expand.
- Marketed as Afinitor, and used when other treatments have not sufficiently controlled renal cell carcinoma.
- It also plays a role in treating breast cancer driven by hormone receptors, as well as certain neuroendocrine tumours.
What is Everolimus?
Everolimus belongs to a class of drugs known as serine/threonine kinase inhibitors. By blocking the mechanistic target of rapamycin (mTor), it suppresses signalling pathways that cancer cells rely on to grow and replicate. Because it targets specific biological pathways, it is considered a precision type of Oncology Support.
What Everolimus is used for
This medication is indicated for several advanced or progressive conditions. It is used to manage Renal Cell Carcinoma when other therapies have not achieved the desired response. It also has clinical use in the management of hormone receptor-positive Breast Cancer and specific Neuroendocrine Tumours.
How does Everolimus work?
Everolimus inhibits the mTor protein. This protein acts as a central switchboard for cell metabolism and division. When inhibited, the cell growth rate is restricted, and the blood supply required for tumour progression is significantly reduced. This targeted approach aims to limit the unchecked proliferation of specific cellular markers.
Everolimus brands and forms
Everolimus is typically available in tablet form. As a complex pharmaceutical agent, consistency in formulation is essential for maintaining blood concentration levels. Patients should review the specific product packaging regarding strengths and usage.
Safety overview for Everolimus
What to check before using this medicine
Patients should identify any history of severe respiratory issues, liver impairment, or existing infections before starting treatment. Regular monitoring of blood counts and metabolic markers is common.
Possible reactions and tolerability
Common observations include fatigue, inflammation of the mucosal lining, or skin rashes. Gastrointestinal distress is also reported by some users as their body adapts to the medication.
Interactions and health factors
Everolimus may interact with substances that affect liver enzyme activity or those that alter immune system function. Product labelling and verified clinical sources remain the correct references for specific contraindications, interactions and reactions.